References
- Chang, J. W. and Yang, D. R., "Metastable Zone Prediction Model for Industrial Crystallization," KIC News, 10(5), 25-30 (2007).
- Sarma, B., Chen, J., Hsi, H.-Y. and Myerson, A. S., "Solid Forms of Pharmaceuticals: Polymorphs, Salts and Cocrystals," Korean J. Chem. Eng., 28(2), 315-322(2011). https://doi.org/10.1007/s11814-010-0520-0
- Liu, X., Sun, D., Wang, F., Wu, Y. J., Chen, Y. and Wang, L., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined FBRM-PVM-NIR," Journal of Pharmaceutical Sciences, 100(6), 3(2011).
- Lee, M.-J., Wang, I.-C., Kim, M.-J., Kim, P., Song, K.-H., Chun, N.-H., Park, H.-G. and Choi, G. J., "Controlling the Polymorphism of Carbamazepine-saccharin Cocrystals Formed During Antisolvent Cocrystallization Using Kinetic Parameters," Korean J. Chem. Eng., 32(9), 1910-1917(2015). https://doi.org/10.1007/s11814-014-0384-9
- Genck, W., Make The Most of Antisolvent Crystallization, Chemical Processing, Article, Nov 08, 2010.
- http://sdic.sookmyung.ac.kr/drug_monograph/view.asp?id=713.
- Surwase, S. A., Boetker, J. P., Saville, D., Boyd, B. J., Gordon, K. C., Peltonen, L. and Strachan, C. J., "Indomethacin: New Polymorphs of an Old Drug," Mol. Pharmaceutics, 10, 4472-4480 (2013). https://doi.org/10.1021/mp400299a
- Khomane, K. S., More, P. K., Raghavendra, G. and Bansal, A. K., "Molecular Understanding of the Compaction Behavior of Indomethacin Polymorphs," Mol. Pharmaceutics, 10, 631-639(2013). https://doi.org/10.1021/mp300390m
-
Carpentier, L., Decressain, R., Desprez, S. and Descamps, M., "Dynamics of the Amorphous and Crystalline
${\alpha}-$ ,$\gamma$ -Phases of Indomethacin," J. Phys. Chem. B, 110, 457-464(2005). - Csermely, P., Korcsmaros, T. Kiss, H. J., London, G. and Nussinov, R., "Structure and Dynamics of Molecular Networks: A novel Paradigm of Drug Discovery: A comprehensive Review," Pharmacol. Ther., 138(3), 333-408(2013). https://doi.org/10.1016/j.pharmthera.2013.01.016
- Stegemann, S., Leveiller, F., Franchi, D., De Jong, H. and Linden, H., "When Poor Solubility Becomes an Issue: From early Stage to Proof of Concept," Eur. J. Pharm. Sci., 31(5), 249-261(2007). https://doi.org/10.1016/j.ejps.2007.05.110
- Di, L., Fish, P. V. and Mano, T., Bridging Solubility Between Drug Discovery and Development., Drug Discovery Today, 486-495(2012).
- Turner, J. R. Drug Discovery. In New Drug Development; Springer: New York, pp 21-34(2010).
- Li, P. and Zhao, L., "Developing Early Formulations: Practice and Perspective," Int. J. Pharmaceutics, 341(1-2), 1-19(2007). https://doi.org/10.1016/j.ijpharm.2007.05.049
- Baird, J. A., Van Eerdenbrugh, B. Taylor, L. S., A classification System to Assess the Crystallization Tendency of Organic Molecules From Undercooled Melts," J. Pharm. Sci., 2010, 99 (9), 3787-3806(2010). https://doi.org/10.1002/jps.22197
- Engers, D., Teng, J., Jimenez-Novoa, J., Gent, P., Hossack, S., Campbell, C., Thomson, J., Ivanisevic, I., Templeton, A., Byrn, S., Newman, A., A solid-state Approach to Enable Early Development Compounds: Selection and Animal Bioavailability Studies of an Itraconazole Amorphous Solid Dispersion," J. Pharm. Sci., 99(9), 3901-3922(2010). https://doi.org/10.1002/jps.22233
- Neervannan, S., "Preclinical Formulations for Discovery and Toxicology: Physicochemical Challenges," Expert Opin. Drug Metab. Toxicol., 2(5), 715-731(2006). https://doi.org/10.1517/17425255.2.5.715
- Hancock, B. C. and Zografi, G., "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," J. Pharm. Sci., 86(1), 1-12(1997). https://doi.org/10.1021/js9601896
- Laitinen, R., Lobmann, K., Strachan, C. J., Grohganz, H. and Rades, T., "Emerging Trends in the Stabilization of Amorphous Drugs," Int. J. Pharmaceutics, 453, 65-79(2013). https://doi.org/10.1016/j.ijpharm.2012.04.066
- Bhugra, C. and Pikal, M. J., "Role of Thermodynamic, Molecular and Kinetic Factors in Crystallization From the Amorphous State," J. Pharm. Sci., 97(4), 1329-1349(2008). https://doi.org/10.1002/jps.21138
- Savolainen, M., Kogermann, K., Heinz, A., Aaltonen, J., Peltonen, L., Strachan, C. and Yliruusi, J., "Better Understanding of Dissolution Behaviour of Amorphous Drugs by in Situ Solid-state Analysis Using Raman Spectroscopy," Eur. J. Pharm. Biopharm., 71(1), 71-79(2009). https://doi.org/10.1016/j.ejpb.2008.06.001
- Wu, T., Sun, Y., Li, N., De Villiers, M. M. and Yu, L., "Inhibiting Surface Crystallization of Amorphous Indomethacin by Nano Coating," Langmuir, 23(9), 5148-5153(2007). https://doi.org/10.1021/la070050i
- Alonzo, D., Zhang, G., Zhou, D., Gao, Y. and Taylor, L., "Understanding the Behavior of Amorphous Pharmaceutical Systems During Dissolution," Pharm. Res., 27(4), 608-618(2010). https://doi.org/10.1007/s11095-009-0021-1
- Greco, K. and Bogner, R., "Crystallization of Amorphous Indomethacin During Dissolution: Effect of Processing and Annealing," Mol. Pharmaceutics, 7(5), 1406-1418(2010). https://doi.org/10.1021/mp1000197
- Andronis, V., Yoshioka, M. and Zografi, G., "Effects of Sorbed Water on the Crystallization of Indomethacin From the Amorphous State," J. Pharm. Sci., 86(3), 346-351(1997). https://doi.org/10.1021/js9602711
- Andronis, V. and Zografi, G., "Crystal Nucleation and Growth of Indomethacin Polymorphs From the Amorphous State," J. Non-Cryst. Solids, 271(3), 236-248(2000). https://doi.org/10.1016/S0022-3093(00)00107-1
- Hancock, B. C., Shamblin, S. L. and Zografi, G., "Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition Temperatures," Pharm. Res., 12(6), 799-806(1995). https://doi.org/10.1023/A:1016292416526
- Borka, L., "The Polymorphism of Indomethacin, New Modifications, Their Melting Behaviour and Solubility," Acta Pharm. Suec., 11, 295-303(1974).
- Lin, S. Y., "Isolation and Solid-state Characteristics of a New Crystal Form of Indomethacin," J. Pharm. Sci., 81(6), 572-576 (1992). https://doi.org/10.1002/jps.2600810622
- Takiyama, H., Minamisono, T. Osada, Y. and Matsuoka, M., "Operation Design for Controlling Polymorphism in the Anti-solvent Crystallization by Using Ternary Phase Diagram," Chem. Eng. Res. Design. 88, 1242-1247(2010). https://doi.org/10.1016/j.cherd.2009.09.011
- Wang, X., de Armas, H. N., Blaton, N., Michoel, A., den Mooter, G. V., "Phase Characterization of Indomethacin in Binary Solid Dispersions with PVP VA64 or Myrj 52," International Journal of Pharmaceutics, 345, 95-100(2007). https://doi.org/10.1016/j.ijpharm.2007.05.046
- Chen, X., Morris, K. R., Griesser, U. J., Byrn, S. R. and Stowell, J. G., "Reactivity Differences of Indomethacin Solid Forms with Ammonia Gas," J. Am. Chem. Soc., 124, 15012-15019(2002). https://doi.org/10.1021/ja017662o
-
Qi, S. and Craig, D. Q. M., "The Development of Modulated, Quasi-Isothermal and Ultraslow Thermal Methods as a Means of Characterizing the
$\alpha$ to$\gamma$ Indomethacin Polymorphic Transformation," Mol. Pharmaceutics, 9, 1087-1099(2012). https://doi.org/10.1021/mp2003412 - Majid Saeedi, Jafar Akbari, Katayoun Morteza-Semnani, Reza Enayati-Fard, Shirin Sar-Reshteh-dar and Ala Soleymania, "Enhancement of Dissolution Rate of Indomethacin: Using Liquisolid Compacts," Iran J Pharm Res., 10(1), 25-34(2011).
- Alsaidan, S. M., Alsughayer, A. A. and Eshra, A. G., "Improved Dissolution Rate of Indomethacin by Adsorbents," Drug Dev. Ind. Pharm., 24, 389-394(1998). https://doi.org/10.3109/03639049809085635
- Chun, N.-H., Wang, I.-C., Lee, M.-J., Jung, Y.-T., Lee, S., Kim, W.-S. and Choi, G. J., "Characteristics of Indomethacin-Saccharin (IMC-SAC) Co-Crystals Prepared by an Anti-Solvent Crystallization Process," European Journal of Pharmaceutics and Biopharmaceutics, 85(3), 854-861(2013). https://doi.org/10.1016/j.ejpb.2013.02.007
- Wang, I.-C., Lee, M.-J., Sim, S.-J., Kim, W.-S., Chun, N.-H. and Choi, G. J., "Anti-Solvent Co-Crystallization of Carbamazepine and Saccharin," International Journal of Pharmaceutics, 450(1-2), 311-322(2013). https://doi.org/10.1016/j.ijpharm.2013.04.012
- De Beer, T. R., Baeyens, W. R., Ouyang, J., Vervaet, C. and Remon, J. P., "Raman Spectroscopy as a Process Analytical Technology Tool for the Understanding and the Quantitative in-line Monitoring of the Homogenization Process of a Pharmaceutical Suspension," Analyst., 131(10), 1137-44(2006). https://doi.org/10.1039/b605299a
- Kim, J. Y. and Kwon, K., "A Study on the Comparison of Korea GMP with PIC/S GMP for Enhancing International Competecy of Medicinal Product Quality," Yakhak Hoeji, 57(6), 432-441 (2013).
- http://www.dailypharm.com/News/184408.
- http://www.yonhapnews.co.kr/bulletin/2016/07/27/0200000000AKR20160727096700017.HTML?input=1195m.
- Kelly, A. L., Gough, T., Dhumal, R. S., Halsey, S. A., Paradkar, A., "Monitoring Ibuprofen-Nicotinamide Cocrystal Formation During Solvent Free Continuous Cocrystallization (SFCC) Using Near Infrared Spectroscopy as a PAT Tool," Int. J. Pharm., 426(1-2), 15-20(2012). https://doi.org/10.1016/j.ijpharm.2011.12.033
- U. S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry PAT-A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, (http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070305.pdf).
- Su, M., Wang, L., Sun, H. and Wang, J. K., "FBRM and PVM Investigations of the Double Feed Semi-Batch Crystallization of 6-Aminopenicillanic Acid," Frontiers of Chemical Engineering in China, 3(3), 282-288(2009). https://doi.org/10.1007/s11705-009-0018-7
- Liu, X., Sun, D., Wang, F., Wu, Y. J. and Chen, Y., "Monitoring of Antisolvent Crystallization of Sodium Scutellarein by Combined Fbrm-pvm-nir," J. Pharmaceutical Sci., 100(6), (2011).
- Leyssens, T., "Carine Baudry and Maria Luisa Escudero Hernandez, Optimization of a Crystallization by Online FBRM Analysis of Needle-Shaped Crystals," Org. Process Res., 413-426(2011).
- Jia, C.-Y., Yin, Q.-X., Zhang, M.-J., Wang, J.-K. and Shen, Z.-H., "Polymorphic Transformation of Pravastatin Sodium Monitored Using Combined Online FBRM and PVM," Organic Process Research & Development, 12(6), (2008).